THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
Reporter Jeff Krasner explains the basis of the Genzyme shareholder lawsuit.

Genzyme to pay $64m to settle buyback claims

Tracking stock at heart of dispute with shareholders

By Jeffrey Krasner
Globe Staff / August 10, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Genzyme Corp. will pay $64 million to settle claims that the Cambridge biotech company schemed to buy back its Genzyme Biosurgery division from shareholders for less than it was worth. (Full article: 552 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass